Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 26

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 26
---
 January 8, 2025, and excludes:

| ● | 61,080                                                 
 shares of Common Stock underlying outstanding options; |

| ● | 408,801                                                                                                                           
 shares of Common Stock issuable under our 2016 Plan and our 2024 Plan, which includes 408,801 shares of Common Stock reserved for 
 issuance under our 2016 Plan and our 2024 Plan;                                                                                   |

| ● | 5,272                                                                                                                            
 shares of Common Stock issuable under our 2024 ESPP, which includes 5,272 shares of Common Stock reserved for issuance under our 
 2024 ESPP;                                                                                                                       |

| ● | 95,186                                                                                               
 shares of Common Stock issuable upon the exercise of Public Warrants and Private Placement Warrants; |

| ● | 335,802                                                                                                                              
 shares of Common Stock issuable upon the exercise of Common Warrants issued in the offerings of our Series A Preferred Stock, Series 
 B Preferred Stock and Series C Preferred Stock;                                                                                      |

| ● | 626,953                                                                                                                           
 shares of Common Stock issuable upon conversion of the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred 
 Stock;                                                                                                                            |

| ● | Up to 4,000,000                                                                                                                    
 shares of Common Stock issuable upon the exercise of Offered Common Warrants issued in this offering described in this prospectus; 
 and                                                                                                                                |

| ● | Up                                                                                                                                  
 to 4,000,000 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants, if issued in this offering described in this 
 prospectus.                                                                                                                         |

8 RISK FACTORS Investing in our securities involves a high degree of risk. Before you decide to invest in our securities, you should consider carefully the risks described below, together with the other information contained in this prospectus, including our financial statements and the related notes appearing at the end of this prospectus. We believe the risks described below are the risks that are material to us as of the date of this prospectus. If any of the following risks actually occur, our business, results of operations and financial condition would likely be materially and adversely affected. In these circumstances, the market price of our securities could decline, and you may lose part or all of your investment. Risks Related to this Offering There is no public market for Offered Common Warrants or the Pre-Funded Warrants to purchase shares of our Common Stock being offered by us